Development and application of in vitro methods for evaluating respiratory irritants.



Douglas C. Wolf, D.V.M., Ph.D., FIATP, ATS Senior Fellow Product Safety Syngenta Crop Protection, LLC

doug.wolf@syngenta.com

Describing the problem

Repeat dose 90-day inhalation study is a regulatory requirement.

No new or additional information will be forthcoming from such a study that will improve human safety assessment.

No additional systemic risk from inhalation exposure.


Contact irritation in respiratory tract.

Long history of safe use, widely-used since 1966.

Question to Answer


What is the human health risk from intermediate- to long-term inhalation exposure to chlorothalonil?





Sauve-Ciencewicki et al., Reg Tox Pharm 101:187-193, 2019

syngenta





Problem Statement

A new approach method can be developed and would be suitable to inform inhalation toxicity in lieu of a sub-chronic whole animal inhalation study.



Source to Outcome Approach

• Source

- Evaluate the particle size distribution of pesticide applications.

• Exposure

- Characterize aerosols captured on personal sampling devices.

Dosimetry


- Calculate deposition in human airways using Computational Fluid Dynamics (CFD) model.

Outcome

- Predict human inhalation toxicity incorporating spray particle size.










Pesticide Exposure


- Exposure data is commonly collected from agricultural workers using an OSHA Versatile Sampler (OVS) tube
- Typically, the OVS tube data is only reported as total concentration, without consideration of particle size
 - What is the particle size distribution captured by this device?
- Studies of spray particle size were undertaken at Syngenta to compare OVS tube with standard sizing methods





Flack et al., J Agri Safety Health 25:91-103, 2019

Human Respiratory Tract




Adapted from: Kolanjiyil and Kleinstreuer J Biomech Eng. 2013 Dec;135(12):121003

9



Regional Deposition in Humans




- Aerosols associated with worker exposures largely deposit in nasal vestibule
 - Peak regional airway exposures at 10-15 µm sized aerosols (excluding the vestibule)
- <20% of the regional airway surfaces receive any aerosol deposition at a high, 1 mg/L exposure



Human CFD/Aerosol Simulation (50 µm MMAD, 4 mg/L)


% of Inhaled Mass Deposited by Location in Respiratory Tract

99.7% Deposited in Nose, Pharynx, Larynx
0.0007% Deposited in Remaining Airways
0% Escape the 3D Lung
0.3% Remain suspended in airways at end of inhalation





Adverse Outcome Pathway leading to Cell Death






MucilAir[™] 3D *in vitro* model

- 3D model of the human airway epithelium formed from differentiated primary human cells
- Measures a variety of membrane and cell damage endpoints as markers of irritation

Trans-epithelial electrical resistance (TEER): measures the integrity of tight junctions between cells in the membrane

- Lactate dehyrogenase (LDH): An enzyme present in most cells released when cells suffer cytotoxic membrane damage
- Resazurin metabolism: reduced to a fluorescent product in viable cells used as a measure of metabolic

competence



https://www.epithelix.com/



Design of MultiDonor MucilAir[™] study

- Endpoints: TEER, LDH, and resazurin metabolism
- Tissues from 5 separate donors
- 24 hour topical exposure
- Chlorothalonil applied as Bravo 720 formulation
- 10 concentrations / donor
- 6 replicates / concentration / donor

Dose Level	Chlorothalonil Concentration (mg/L)		
1	2		
2	5		
3	8		
4	13		
5	20		
6	32		
7	50		
8	79		
9	126		
10	200		




MultiDonor MucilAir[™] study results

- Individual donor responses were very similar across the 5 donors used in this study, suggesting low inter-donor variability in sensitivity
- All endpoints (TEER, LHD, resazurin) responded similarly to chlorothalonil challenge
- Multiple BMD approaches were examined, BMD_{1SD} was selected through consultation with the US EPA

	BMD _{1SD} (mg/cm²)				
Donor	TEER	LDH	Resazurin	Mean	
1	0.00463	0.00611	0.00603	0.00555	
2	0.00480	0.00840	0.00728	0.00664	
3	0.00798	0.00815	0.00830	0.00814	
4	0.00996	0.00823	0.00384	0.00680	
5	0.01125	0.00919	0.01024	0.0102	
Mean	0.00724	0.00794	0.00678	0.00730	




Calculating a Human Equivalent Concentration






Accurate and Health Protective Risk Assessments Based on human *in vitro* Assay and human *in silico* Model



17

Exposure Based Inhalation Model (IATA)



Outcome

This Source to Outcome Analysis Addresses:

Inhalation Study Requirement

Point of Departure

Uncertainty Factors

Database LOAEL to NOAEL Interspecies



Evaluation of a Proposed Approach to Refine the Inhalation Risk Assessment for Point of Contact Toxicity: A Case Study Using a New Approach Methodology (NAM)

Date and Time

Tuesday 12/04/2018 9:00AM EST to Friday 12/07/2018 5:00PM EST

https://www.regulations.gov/docket?D=EPA-HQ-OPP-2018-0517



Syngenta Collaboration External Partners

Toxicology

- Alex Charlton
- Bob Parr-Dobrzanski
- Douglas Wolf

Modeling

Paul Hinderliter

Risk Assessment

- Sheila Flack
- Tharacad Ramanarayanan

Application Technology

Mark Ledson

Charles River Labs

Epithelix

NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

Pacific Northwest National Lab

Research Triangle Institute

USEPA




Thank You

Bringing plant potential to life







HESI RISK ASSESSMENT SUMMIT 2020

The HESI RISK21 Committee is pleased to invite you to the first **Risk Assessment Summit**, which will be held on **February 18-19,2020**, in **Washington**, DC!

The Summit will convene a broad group of stakeholders to discuss risk assessment approaches

This site uses cookies to provide you with a personalized browsing experience. By clicking "I Agree" or continuing to use the site you agree to allow cookies to be placed and accept the terms set out in our [Privacy Notice]. Please read the Privacy Notice for more information on how we handle information

collected from users and how you can control the use of such information.

Cookie settings I Agree

Transparent


Visual

The Summit will be structured around specific case examples presented by government, industry, academic, and NGO stakeholders, to illustrate various real-world applications of these principles in the context of human health and ecological risk assessment (e.g., prioritization, categorization, study design, new product development, risk management and communication, etc.). There will also be a poster session on the evening of February 18th to allow a broader group of attendees to share their case studies.

We would like this meeting to provide a forum to discuss risk assessment challenges, foster collaboration, and leverage expertise to address gaps and needs, and we hope you will join us to learn about lessons and insights in the risk assessment space, and also share your experience with this community of practice.

□ Click Here to Register!

About RISK21®



how the world evaluates chemicals using a riskbased approach. the process


- Use of prior knowledge
- Fit for purpose
- Value of information
- "Enough precision to make the decision"
- Provide a framework that is flexible, transparent, visual

methods

- Actively involved over 120 participants (government, industry, academia, NGOs) through 6 years of work
- Published 8 manuscripts in Critical Reviews in Toxicology
- Reached over 500 participants in 5 countries on three continents via 7 hands-on case-study workshops
- Revised current thinking about how to approach the science and art of risk assessment

communicatio n

Additional illustration and application via case studies
Ongoing dialog on advances and needs



Version 2.0 of the RISK21® Webtool is

Now Available!

21st Century Framewor k

The webtool supports a problem formulation-based, exposure-driven, tiered acquisition approach that leads to an informed decision.

Transpare nt and Consisten

The webtool approach allows users to optimize the use of resources and information available for chemical risk assessment.

Create Custom Plots

Users can interact with the RISK21 webtool application to visualize their own risk data, creating a custom plot which will be displayed on the screen.

RISK21® Roadmap and Matrix

The RISK21 webtool application allows users to input estimated exposure and toxicity data for each chemical, and will plot the intersection area, overlaying a risk matrix represented as a heat map.

HESI® and RISK21® are registered United States of America trademarks of the Health and Environmental Sciences Institute



https://risk21.org/[12/29/2019 8:47:16 PM]